New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...
Dealbreaker on MSN
Takeda R&D exec explains how $1.2B deal could become one of the biggest bargains in drug history
Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this ...
GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
14d
FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis
Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...
DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback